peer-OX-i-kam 
Contraindicated in:
Use Cautiously in:
CV: edema, HF, hypertension, MYOCARDIAL INFARCTION, STROKE.
Derm: DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS), EXFOLIATIVE DERMATITIS, rash, STEVENS-JOHNSON SYNDROME, TOXIC EPIDERMAL NECROLYSIS.
EENT: blurred vision, tinnitus.
F and E: hyperkalemia.
GI: discomfort, dyspepsia, nausea, vomiting, anorexia, constipation, diarrhea, flatulence, GI BLEEDING, HEPATOTOXICITY.
GU: renal failure.
Hemat: blood dyscrasias, prolonged bleeding time.
Neuro: drowsiness, headache, dizziness.
Drug-Drug:
Drug-Natural Products:
Absorption: Well absorbed from the GI tract.
Distribution: Unknown. Enters breast milk in small amounts.
Metabolism/Excretion: Mostly metabolized by the liver (primarily by CYP2C9). Patients who are poor CYP2C9 metabolizers may have reduced metabolism of piroxicam which may lead to ↑ toxicity). Minimal amounts excreted unchanged by the kidneys.
Half-life: 50 hr.
| ROUTE | ONSET | PEAK | DURATION |
|---|---|---|---|
| PO (analgesic effect) | 1 hr | unknown | 48–72 hr |
| PO (anti-inflammatory effect) | 7–12 days | 2–3 wk† | unknown |
NDC Code*